Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

Benzinga Newsdesk www.benzinga.com Negative 78.3%

Neg 78.3% Neu 0% Pos 0%

Wedbush analyst David Nierengarten reiterates Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $60 price target.